GLP-1 Medicines and Mental Health Changes
Changes in Psychiatric Symptoms, Eating Disorder Behaviors, and Health Behaviors Following Six Months of GLP-1 Treatment for Obesity
Lead sponsor
Assets
Semaglutide / Tirzepatide
Listed sites
1
Recruiting sites
-
Actual enrollment
90
Study population
Obesity / overweight
Eligibility highlights
-
Primary endpoint
•Beck Depression Inventory-2
Registered trial locations
Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.
Identifiers
Registered as
Timeline
Milestones
Assets
Investigational agents
Who this study enrolls
Who can enroll
Inclusion criteria
Exclusion criteria
Endpoints (1)
What's being measured
Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.
Patient-reported / QoL
1 endpointBeck Depression Inventory-2
Time frame:Six months
change from baseline, improvement
Provenance
Sources
Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.